146 related articles for article (PubMed ID: 16904570)
1. Keeping apples and oranges separate: reassessing clinical trials that use composite end points as their primary outcome.
Chan PS; Nallamothu BK; Hayward RA
J Am Coll Cardiol; 2006 Aug; 48(4):850; author reply 851-2. PubMed ID: 16904570
[No Abstract] [Full Text] [Related]
2. Unconventional end points in cardiovascular clinical trials: should we be moving away from morbidity and mortality?
Cohn J; Cleland JG; Lubsen J; Borer JS; Steg PG; Perelman M; Zannad F
J Card Fail; 2009 Apr; 15(3):199-205. PubMed ID: 19327621
[TBL] [Abstract][Full Text] [Related]
3. What we want versus what we can get: a closer look at failure time endpoints for cardiovascular studies.
Song R; Cook TD; Kosorok MR
J Biopharm Stat; 2008; 18(2):370-81. PubMed ID: 18327727
[TBL] [Abstract][Full Text] [Related]
4. [Composite endpoints in clinical trials].
Ferreira-González I; Alonso-Coello P; Solà I; Pacheco-Huergo V; Domingo-Salvany A; Alonso J; Montori V; Permanyer-Miralda G
Rev Esp Cardiol; 2008 Mar; 61(3):283-90. PubMed ID: 18361902
[TBL] [Abstract][Full Text] [Related]
5. Determining the most appropriate components for a composite clinical trial outcome.
Bethel MA; Holman R; Haffner SM; Califf RM; Huntsman-Labed A; Hua TA; McMurray J
Am Heart J; 2008 Oct; 156(4):633-40. PubMed ID: 18926145
[TBL] [Abstract][Full Text] [Related]
6. Informed choice of composite end points in cardiovascular trials.
Gómez G; Gómez-Mateu M; Dafni U
Circ Cardiovasc Qual Outcomes; 2014 Jan; 7(1):170-8. PubMed ID: 24425702
[TBL] [Abstract][Full Text] [Related]
7. End points for cardiovascular drug trials in pediatric patients.
Sinaiko AR; Lauer RM; Sanders SP
Am Heart J; 2001 Aug; 142(2):229-32. PubMed ID: 11479459
[No Abstract] [Full Text] [Related]
8. The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention.
Kip KE; Hollabaugh K; Marroquin OC; Williams DO
J Am Coll Cardiol; 2008 Feb; 51(7):701-7. PubMed ID: 18279733
[TBL] [Abstract][Full Text] [Related]
9. Temporal Trends in Use of Composite End Points in Major Cardiovascular Randomized Clinical Trials in Prominent Medical Journals.
Tan NS; Ali SH; Lebovic G; Mamdani M; Laupacis A; Yan AT
Circ Cardiovasc Qual Outcomes; 2017 Oct; 10(10):. PubMed ID: 28954803
[TBL] [Abstract][Full Text] [Related]
10. A global ranking approach to end points in trials of mechanical circulatory support devices.
Felker GM; Anstrom KJ; Rogers JG
J Card Fail; 2008 Jun; 14(5):368-72. PubMed ID: 18514927
[TBL] [Abstract][Full Text] [Related]
11. Power play.
Reider B
Am J Sports Med; 2005 Nov; 33(11):1637-8. PubMed ID: 16230469
[No Abstract] [Full Text] [Related]
12. A combined superiority and non-inferiority approach to multiple endpoints in clinical trials.
Bloch DA; Lai TL; Su Z; Tubert-Bitter P
Stat Med; 2007 Mar; 26(6):1193-207. PubMed ID: 16791905
[TBL] [Abstract][Full Text] [Related]
13. Documentation of endpoint prevention with combination therapy in hypertension is urgently needed.
Kjeldsen SE; Oparil S; Hedner T; Narkiewicz K
Blood Press; 2007; 16(1):4-5. PubMed ID: 17453745
[No Abstract] [Full Text] [Related]
14. Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?
Dahlöf B; Devereux RB; Kjeldsen SE; Lyle PA; Zhang Z; Edelman JM
Blood Press; 2007; 16(1):6-12. PubMed ID: 17453746
[TBL] [Abstract][Full Text] [Related]
15. Balancing the morbidity benefit of a novel treatment with the potential for harm.
Owen A
QJM; 2006 Mar; 99(3):177-9. PubMed ID: 16490759
[No Abstract] [Full Text] [Related]
16. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
17. [Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?].
Haberbosch W
Herz; 2007 Feb; 32(1):51-7. PubMed ID: 17323035
[TBL] [Abstract][Full Text] [Related]
18. Chronic kidney disease and mortality and morbidity among patients with established cardiovascular disease: a West of Ireland community-based cohort study.
Glynn LG; Reddan D; Newell J; Hinde J; Buckley B; Murphy AW
Nephrol Dial Transplant; 2007 Sep; 22(9):2586-94. PubMed ID: 17452408
[TBL] [Abstract][Full Text] [Related]
19. Recent clinical trials.
Frishman WH
Heart Dis; 2000; 2(1):1-2. PubMed ID: 11794144
[No Abstract] [Full Text] [Related]
20. Rosuvastatin outcomes study JUPITER closes early due to evidence of benefit.
Cardiovasc J Afr; 2008; 19(2):117. PubMed ID: 18516361
[No Abstract] [Full Text] [Related]
[Next] [New Search]
